Contraindicated (1)bortezomib will enhance the degree or influence of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Sturdy or reasonable CYP2C19 inhibitors may well increase mavacamten systemic publicity, resulting in coronary heart failure as a result of systolic dysfunction.If there are actually any glitches in execu